A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Who May Qualify: - Patient understands the procedures and requirements and is willing and able to give willing to sign a consent form for full participation in the study - Adults, male or female, aged 18 to 60 years at time of consent. - Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours) - Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of \<30 - Able to walk unaided and unimpeded in activities of daily living (ADLs) - Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits Who Should NOT Join This Trial: The patient may not enter the study if ANY of the following apply: - Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity - Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity - BMI ≥35 Kg/m2 - Clinically relevant laboratory abnormalities discovered at screening - Haemoglobin \<10g/dL - Platelet count \<100,000/uL - ALT \> 2x ULN - Total bilirubin \>1.5 x ULN - eGFR \<70mls/min/1.73m2 - For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join) - Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics - Currently participating in another interventional influenza or COVID-19 therapeutic trial - Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required) - Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR) - Received live attenuated influenza virus vaccine within 3 weeks prior to study entry Always talk to your doctor about whether this trial is right for you.